Recursion Pharmaceuticals (NASDAQ:RXRX) Stock: Insider Blake Borgeson Sells 40,000 Shares

Key Points

• Director Blake Borgeson sold 40,000 Recursion Pharmaceuticals shares for $155,200 at an average price of $3.88 under a pre-arranged Rule 10b5-1 plan. He retained 6,068,287 shares after the sale.
• Recursion reported quarterly EPS of ($0.22), matching analyst estimates, while revenue of $18.55 million topped the $14.81 million consensus forecast.
• Analysts’ consensus rating is Hold, with an average price target of $8.18; ratings range from Sell to Buy.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) Director Blake Borgeson sold 40,000 shares of the stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $3.88, for a total value of $155,200.00. Following the transaction, the director directly owned 6,068,287 shares in the company, valued at approximately $23,544,953.56. The trade was a 0.65% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, October 6th, Blake Borgeson sold 50,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $4.84, for a total value of $242,000.00.
• On Tuesday, September 1st, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.34, for a total value of $100,200.00.

Recursion Pharmaceuticals Trading Up 5.4%

NASDAQ RXRX traded up $0.20 during trading on Wednesday, hitting $3.88. The stock had a trading volume of 20,553,455 shares, compared to its average volume of 19,663,393. The company has a quick ratio of 5.03, a current ratio of 5.03 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $2.08 billion, a PE ratio of -4.31 and a beta of 1.15. The firm has a 50 day moving average price of $3.76 and a 200 day moving average price of $3.53. Recursion Pharmaceuticals, Inc. has a twelve month low of $2.77 and a twelve month high of $5.24.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The company reported ($0.22) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.22). Recursion Pharmaceuticals had a negative net margin of 697.15% and a negative return on equity of 46.47%. The business had revenue of $18.55 million for the quarter, compared to analysts' expectations of $14.81 million. During the same quarter in the prior year, the company earned ($0.36) earnings per share. As a group, equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -0.93 earnings per share for the current year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several large investors have recently bought and sold shares of the business. MCF Advisors LLC acquired a new position in shares of Recursion Pharmaceuticals in the 2nd quarter valued at $27,000. Park Avenue Securities LLC purchased a new position in shares of Recursion Pharmaceuticals in the 3rd quarter valued at $47,000. Fund Advisors of America Inc FL acquired a new stake in Recursion Pharmaceuticals during the 2nd quarter worth $45,000. Kestra Private Wealth Services LLC acquired a new stake in Recursion Pharmaceuticals during the 3rd quarter worth $58,000. Finally, Sequoia Financial Advisors LLC raised its stake in Recursion Pharmaceuticals by 51.5% during the 1st quarter. Sequoia Financial Advisors LLC now owns 15,162 shares of the company's stock worth $47,000 after acquiring an additional 5,156 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on RXRX. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a research note on Thursday, October 15th. Wall Street Zen upgraded shares of Recursion Pharmaceuticals from a "strong sell" rating to a "sell" rating in a report on Saturday, October 17th. Needham & Company LLC reissued a "buy" rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Monday, October 19th. Finally, Morgan Stanley set a $5.90 price target on shares of Recursion Pharmaceuticals in a research note on Friday, October 16th. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $8.18.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc is a biotechnology company that uses advanced computing, artificial intelligence and automated biology to discover and develop new medicines. The company's platform, known as the Recursion Operating System, combines large-scale biological experimentation with machine learning and data analysis to identify potential drug candidates and characterize how diseases respond to treatments.

Recursion applies its technology to a range of therapeutic areas, including oncology, rare diseases, neuroscience and infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.